by Krystal Jacques | Feb 19, 2025
There are many ways the regenerative potential of cell transplantation therapy can be optimized to pave the route to the clinic. They include, but are not limited to, deciding which cells to transplant and looking at whether we should use fresh cells or cryopreserved...
by Stacey Johnson | Aug 30, 2024
This has never happened before. In eight years of hosting the blog carnival, we have never encountered a situation where the conclusions have been so similar. Given this year’s topic, the optimism is a good thing. So here is our topic: Venture financing in cell...
by Laya Kiani | Jul 11, 2024
Intellectual property (IP) rights in regenerative medicine (RM) are crucial for sparking innovation and staying ahead in a competitive market. Protecting inventions through patents and other IP rights encourages investment by giving inventors exclusive market rights....
by Kevin Robb | Nov 9, 2023
BlueRock Therapeutics has generated considerable media buzz with their announcement of positive Phase I clinical trial data on bemdaneprocel (BRT-DA01), an investigational, stem cell-derived, dopaminergic therapy for Parkinson’s disease. The trial is the result of...
Comments